The ANCO Board of Directors has educated itself and considered its role in payer provider partnerships—learning about the available compliance models used by payers and vendors in the payer provider partnership space and exercising its due diligence with respect to the various vendors on behalf of the membership.

It is the consensus of the Board that ANCO should take an active but limited role in payer provider partnerships.

In summary, ANCO’s role will be limited to informing, educating, and recommending that members proactively take advantage of front-end compliance programs such as Innovent Oncology and Via Oncology and negotiate payer provider partnerships with their major third-party payers.

ANCO has invited these organizations to work with ANCO in bringing comprehensive information about their pathways programs and how they have worked with practices and third-party payers to the membership. While the Board does not endorse one of these organizations over the other, it does endorse the concept of pathways and front-end (i.e., clinical decision point) compliance models such as those offered by these two organizations over all other models and vendors or potential partners involved in payer provider partnerships.

Five Reasons to Take Action with ANCO's Payer Provider Partnership Strategy
by Dawn Holcombe, MBA, FACMPE, ACHE, President, DGH Consulting

An Introduction to Innovent Oncology
by Sean Taylor, Director of Business Development, Western US, US Oncology

An Introduction to Via Oncology
by Kathy Lokay, President, Via Oncology